← Leaderboards
Jun Wang
James J Peters Va Medical Center
$3,963,331
Attributed
$5,737,826
Total exposure
9
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.5M · FY2014–25$5M$3.8M$2.5M$1.3M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,737,826 · 4
VA$0 · 5
By mechanism
RF1$3,548,990 · 1
P50$1,385,670 · 1
R21$464,750 · 1
R03$338,416 · 1
I01$0 · 3
I21$0 · 2
Top collaborators
- Carole S Morel1 shared
Most similar at James J Peters Va Medical Center
Same institution · by research overlap
- Fatemeh G Haghighi$6,975,089
- Melissa J Nirenberg$0
- Effie M Mitsis$0
Others in their field
Top investigators on “Brain”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Michael W Weiner · Northern California Institute Res &Educ$149,959,854
- David A Bennett · Rush University Medical Center$148,375,056
- David Heimbrook · Leidos Biomedical Research, Inc.$145,442,397
- Walter John Curran · Thomas Jefferson University$114,442,832
- Hongkui Zeng · Allen Institute$113,960,965
Research focus
BrainMediatingAffectSynapsesPhenotypeSynaptic PlasticityMolecularAlzheimer&AposVeteransIn VivoBaseMouse ModelResponseChronicMental DepressionSynaptic FunctionStressBehaviorPrevalencePreventImpaired CognitionProtocols DocumentationCognitive FunctionFemale
Grant awards (25)
Promoting stress-resilience prevents AD-associated neuropsychiatric symptoms$3,548,990
RF1 · FY2025 · AG · contact PI
Sex-specific role of CCL5/CCR5 axis in depression and its therapeutic implication$0
I01 · FY2025 · VA · contact PI
Molecular mechanisms of pathological aging of human brain and adipose and their inter-organ communication$464,750
R21 · FY2024 · AG · contact PI
Sex-specific role of CCL5/CCR5 axis in depression and its therapeutic implication$0
I01 · FY2024 · VA · contact PI
Repurposing of Maraviroc for the treatment of neuropathic pain$0
I21 · FY2024 · VA · contact PI
Sex-specific role of CCL5/CCR5 axis in depression and its therapeutic implication$0
I01 · FY2023 · VA · contact PI
Development of dihydrocaffeic acid and malvidin- 3 - glucoside for the treatment of depression and anxiety disorders$0
I01 · FY2023 · VA · contact PI
Sex-specific role of CCL5/CCR5 axis in depression and its therapeutic implication$0
I01 · FY2022 · VA · contact PI
Repurposing of Maraviroc for the treatment of neuropathic pain$0
I21 · FY2022 · VA · contact PI
Development of dihydrocaffeic acid and malvidin- 3 - glucoside for the treatment of depression and anxiety disorders$0
I01 · FY2022 · VA · contact PI
Contribution of peripheral immune dysregulation to Alzheimer's disease$338,416
R03 · FY2021 · AG · contact PI
Development of dihydrocaffeic acid and malvidin- 3 - glucoside for the treatment of depression and anxiety disorders$0
I01 · FY2021 · VA · contact PI
Epigenetic Mechanism Linking Diabetes and Cognitive Dysfunction$0
I01 · FY2021 · VA · contact PI
Epigenetic Mechanism Linking Diabetes and Cognitive Dysfunction$0
I01 · FY2020 · VA · contact PI
Development of dihydrocaffeic acid and malvidin- 3 - glucoside for the treatment of depression and anxiety disorders$0
I01 · FY2020 · VA · contact PI
Pasinetti: Core C; Behavioral Phenotyping and Electrophysiology (Wang)$282,842
P50 · FY2019 · AT · contact PI
Epigenetic Mechanism Linking Diabetes and Cognitive Dysfunction$0
I01 · FY2019 · VA · contact PI
Pasinetti: Core C; Behavioral Phenotyping and Electrophysiology (Wang)$277,944
P50 · FY2018 · AT · contact PI
Epigenetic Mechanism Linking Diabetes and Cognitive Dysfunction$0
I01 · FY2018 · VA · contact PI
Pasinetti: Core C; Behavioral Phenotyping and Electrophysiology (Wang)$274,952
P50 · FY2017 · AT · contact PI
Epigenetic Mechanism Linking Diabetes and Cognitive Dysfunction$0
I01 · FY2017 · VA · contact PI
Pasinetti: Core C; Behavioral Phenotyping and Electrophysiology (Wang)$275,770
P50 · FY2016 · AT · contact PI
Pasinetti: Core C; Behavioral Phenotyping and Electrophysiology (Wang)$274,162
P50 · FY2015 · AT · contact PI
Development of Carvedilol Analogs with Anti-Aggregation Activity for Treating AD$0
I21 · FY2015 · VA · contact PI
Development of Carvedilol Analogs with Anti-Aggregation Activity for Treating AD$0
I21 · FY2014 · VA · contact PI